Authors
Latest:
Purposeful Partnerships for Post-COVID EraPharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.
Latest:
An Integrated Patient Advocacy Strategy With Transparent CommunicationA roadmap for cohering patient perspectives.
Latest:
How a Top Pharma Pressure Tests a New Platform to Unify Diverse R&D Data AnalyticsJune 24, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST Rafael Fernandez, PhD, Associate Director-Merck & Co. IT, and Gottfried Schroeder, PhD, Associate Principal Scientist at Merck & Co. (Quantitative Biosciences), join PerkinElmer’s Christof Gaenzler, PhD, for a discussion of how they conducted in-depth testing of a new data analytics workflow to streamline data capture and analysis across diverse formats covering a wide range of biochemical, biophysical and cellular assay types.
Latest:
mRNA Technology: First COVID-19, Now CancerHaving proved its efficacy against COVID-19, mRNA technology is positioned to combat another insidious human adversary: cancer.
Latest:
Comparing Registry and Electronic Health Record Data for Real-World Evidence Generation: Heart Failure as a Case StudyContrasting the view of heart failure patients as seen from the perspectives of two large but distinct sources of real-world data: the Veradigm Cardiology Registry and Practice Fusion
Latest:
Closing the Gaps in Pre-Approval Information Exchange to Accelerate Product Success and Patient AccessGaps remain in the pre-approval information process leave payers without all of the information they need to make the proper decisions.
Latest:
Pharma Industry Execs React to President Trump’s 60-Day MFN DeadlineMembers of the industry believe the US should remain an innovation-friendly market.
Latest:
Fast-Tracking Development: How Life Sciences Will Drive Speed in 2025Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.
Latest:
National Recovery Month is a Time for ActionWith the headlines focused on COVID-19, many may have forgotten about the escalating epidemic of substance use disorder. National Recovery Month is a time to bring this issue back to the top of the agenda, raise awareness, and drive action, writes Richard Pops, CEO of Alkermes.
Latest:
Bridging the Health Equity Gap in Clinical DevelopmentThe COVID-19 pandemic has exposed global health inequities and is driving life sciences companies to establish strategies and better leverage data to address systemic causes and improve equity in access to healthcare innovations, particularly in clinical trials.
Latest:
Escaping the “Valley of Death:” The Funding Process for Biotechnology CompaniesChristopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.
Latest:
7 Proven Digital Programs to Supercharge Pharma Value Chain This YearEach program strengthens the pharma value chain, impacting the core areas of clinical development, supply chain, and manufacturing and commercial engagement.
Latest:
The Growth of International Arbitration in the Life Sciences SectorIn an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.
Latest:
A New Era in Clinical TrialsCurrent industry challenges present an opportunity for innovation and the adoption of new solutions, particularly in addressing barriers related to patient recruitment, engagement, and retention.
Latest:
Revitalizing Mature Pharma Brands: 5 Winning StrategiesStrategies that can help maintain and grow your market share. Plus how to adapt to new competitive pressures and evolving customer needs.
Latest:
A Risk-Reward Reset: Getting Serious About Social MediaAs the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
Latest:
The Surprising Inefficiency of Field DeploymentsDeployments are often built on the concept that growth comes from new prescribers, which may be limiting their success.
Latest:
FDA Inspection and Enforcement Developments During the COVID-19 PandemicMitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
Latest:
Patient-First Approach Ensures People With Rare Disorders Receive Better Care and OutcomesImproving the patient experience for those with orphan diseases through a patient-first approach.
Latest:
Proactive Engagement: How AI-Driven Alerts are Transforming HCP OutreachThe benefits for brand teams in bolstering their rapid-response capability.
Latest:
The Non-Personal Promotion EquationNon-personal promotion is a foundational component of most brands’ omnichannel marketing strategy.
Latest:
Building Effective Real World Evidence Studies to Support New Indications for Established ProductsThe use of real-world evidence can prevent pharma companies from performing studies based on flawed data.
